You are here

Proteoglycans: key regulators of pulmonary inflammation and the innate immune response to lung infection.

TitleProteoglycans: key regulators of pulmonary inflammation and the innate immune response to lung infection.
Publication TypeJournal Article
Year of Publication2010
AuthorsGill, S, Wight, TN, Frevert, CW
JournalAnat Rec (Hoboken)
Volume293
Issue6
Pagination968-81
Date Published2010 Jun
ISSN1932-8494
KeywordsAnimals, Humans, Immunity, Innate, Inflammation Mediators, Lung, Mycobacterium tuberculosis, Pneumonia, Bacterial, Proteoglycans, Respiratory Mucosa
Abstract

Exposure to viruses and bacteria results in lung infections and places a significant burden on public health. The innate immune system is an early warning system that recognizes viruses and bacteria, which results in the rapid production of inflammatory mediators such as cytokines and chemokines and the pulmonary recruitment of leukocytes. When leukocytes emigrate from the systemic circulation through the extracellular matrix (ECM) in response to lung infection they encounter proteoglycans, which consist of a core protein and their associated glycosaminoglycans. In this review, we discuss how proteoglycans serve to modify the pulmonary inflammatory response and leukocyte migration through a number of different mechanisms including: (1) The ability of soluble proteoglycans or fragments of glycosaminoglycans to activate Toll-like receptor (TLRs) signaling pathways; (2) The binding and sequestration of cytokines, chemokines, and growth factors by proteoglycans; (3) the ability of proteoglycans and hyaluronan to facilitate leukocyte adhesion and sequestration; and (4) The interactions between proteoglycans and matrix metalloproteinases (MMP) that alter the function of these proteases. In conclusion, proteoglycans fine-tune tissue inflammation through a number of different mechanisms. Clarification of the mechanisms whereby proteoglycans modulate the pulmonary inflammatory response will most likely lead to new therapeutic approaches to inflammatory lung disease and lung infection.

DOI10.1002/ar.21094
Alternate JournalAnat Rec (Hoboken)
PubMed ID20503391
Grant ListR21 RR030249-02 / RR / NCRR NIH HHS / United States